Especially for anti‐CD3‐TRAIL, the anti‐CD3 component can simultaneously activate resting T cells, endowing them with intrinsic cytotoxic effector activity of T cells and leading to granzyme/perforin‐mediated tumor cell lysis. This evidence concerns the gene PRF1 and neoplasm.